$2.20
0.05782.7%
Last update: Nov 11, 4:36 PM
Artelo Biosciences Inc
ARTLNASDAQ
Artelo Biosciences fell 95.8% from $52.92 to $2.20, behind the S&P 500's +9.8%. Its worst day was Mar 26 (−34.2%), and its low came Nov 6 at $1.91.
Nov 11, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-107.19 missed the $-22.14 estimate on $0.00 revenue.
−8.2% · S&P 500 +0.1%
EPS of $37.26 beat the $-42.39 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
+4.8% · S&P 500 +0.7%
Artelo Biosciences shares rose 50.7%, while the S&P 500 fell 1.4%.
+50.7% · S&P 500 −1.4%
Artelo Biosciences closed at its highest level of the year, 79.3% above where the year started.
+230.4%, the year's best day · S&P 500 −1.7%
EPS of $-36.00 missed the $-14.13 estimate on $0.00 revenue.
−21.4% · S&P 500 −1.2%
EPS of $-8.01 was reported on $0.00 revenue.
+3.5% · S&P 500 +0.7%
As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeksApplication expands Artelo’s
+76.1%, on 25M shares, the year's heaviest volume · S&P 500 −0.7%
Artelo Biosciences closed at its lowest level of the year, 96.4% below where the year started.
−7.3% · S&P 500 +0.3%
Where it ended: a close of $2.20 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 24, 2026.
Nothing in the past 12 months.
All ARTL dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ARTL and SPY from Benzinga historical bars. Not investment advice.
